Vittamed is a Boston based medical device company which has developed the first accurate non-invasive Doppler ultrasound-based method of measuring intracranial pressure (ICP) – a key parameter in the monitoring of severe traumatic brain injury and a variety of other neurological conditions, both acute (e.g. stroke, intracerebral and subarachnoid haemorrhage) and chronic (e.g. brain tumours, headaches due to hyper- or hypo-tension). Today, ICP can only be measured by drilling a hole through the skull and inserting a probe into the brain. Given the risks involved with this procedure, this means that measurement of ICP is
currently limited to only severely ill patients, even though it has potential clinical value in neurology clinics, emergency departments and battlefield situations.
Vittamed’s ICP and cerebrovascular autoregulation monitoring products (205 and 505, respectively) have been granted CE marks in Europe in 2014 and its application for a Class 2 US 510K licence is in progress. It has also been adopted by NASA for use in the US Space Programme and by the German Space Agency for use in its Space Programme. Vittamed is currently collaborating with some of the leading neurological hospitals in the US and Europe